European Food Safety Authority
The safety of the food chain is indirectly affected by the welfare of animals, particularly those farmed for food production, due to the close links between animal welfare, animal health and food-borne diseases. The welfare of food producing animals depends largely on how they are managed by humans. In addition to farmed animals, animals used in laboratory tests and wild animals kept in zoos are also protected by harmonised EU standards. The EU is a signatory to the European Convention for the protection of animals kept for farming purposes, adopted by the Council of Europe. The Panel provides independent scientific advice to the European Commission, European Parliament and Member States on all aspects of animal health and animal welfare, chiefly for food producing animals.
The European Commission has mandated EFSA to provide scientific advice on the welfare of a number of farm animal categories including pigs, fish and dairy cows. In an effort to provide a standardised methodology for the risk assessment of animal welfare, EFSA’s AHAW Panel developed its pioneering Guidance giving scientists, veterinarians and all those with an interest in animal welfare a practical, harmonised methodology to assess risks associated with the welfare of animals. The European Commission has called for measurable animal welfare indicators to be developed to reinforce the scientific basis of EU regulation in this field. These welfare indicators will support decision-making on the acceptable conditions for farmed animals and will be used to underpin monitoring and control programmes, implemented at farm level, to guarantee standards of animal health and welfare and to help control diseases. Such factors may include both the resources available to the animal in its environment, for example space or bedding material, or the practices used to manage the animal on the farm, such as how and when the farmer feeds the animal or the procedures in place for weaning.
It is based on the findings of the working group on experimental animals, which underlined the importance of risk assessment approaches in the area of food and feed safety which minimise the use of experimental animals and their suffering and lead towards the replacement of animal testing. Given the close link between the conditions of farmed animals, disease prevalence and food safety, other EFSA Panels work in closely related areas.
Irish Pig Health Society
Its aims are the advancement and dissemination of knowledge concerning all aspects of pig health and production. Each year the Irish Pig Health Society holds its annual symposium and trade fair. Calum is a Technical Sales Manager for Anpario plc with responsibilities for business in Ireland and the UK. Calum has worked for the last 25 years in the Pig Industry both in Ireland and the UK. He has gained experience in pig production, pig genetics, veterinary pharmaceuticals and the feed industry.
Calum joined the Irish Pig Health Society committee in 2009. From a prominent pig farming background, Shane’s family farm 2000 sows across three modern production sites in Kerry including Ireland’s first freedom farrowing commercial pig unit. A year later he graduated from Waterford Institute of Technology with BSc Hons degree where his research focused on PCV2 vaccination in piglets and biosecurity practices on Irish pig farms. Shane is also Secretary of the Irish branch of the European Pig Producers organisation, a member of the Irish Farmer’s Association National Pigs and Pigmeat committee and is currently studying part-time for a Masters in Intensive Livestock Health and Production at the Royal Veterinary College of London. Allison graduated as a veterinary surgeon in 1996 from UCD and after graduation she worked in a specialist pig practice within Ireland, for 3 years.
In 2001, she moved to Yorkshire and worked as a specialist pig vet in practice, until 2005, where she gained her post-graduate ‘Certificate in Pig Medicine’ from the Royal Veterinary College. In 2014, Amy completed her PhD with the University of Warwick and Teagasc which examined the prevalence and risk factors for lameness and limb lesions in Irish pig farms and investigated the effect of feeding a diet specially formulated to the needs of developing gilts on locomotory ability, claw lesions, limb lesions, post mortem joint lesions, bone mineral density and carcass characteristics. Since 2013, Amy has been employed by Teagasc as a Pig Development Officer with the Pig Development Department. She is tasked with providing an advisory, knowledge transfer and education service for Irish pig producers in order to enhance the sustainability of Irish pig meat production.
ArunA biomedical study published in Stroke, exosomes improved recovery in stroked pigs
ArunA Biomedical today announced the publication of data demonstrating that neural stem cell-derived extracellular vesicles improved tissue and functional recovery in pigs following ischemic stroke. Published in today’s issue of Stroke, this is the first ever study to evaluate the therapeutic potential of human NSC EVs in a large animal model representative of the human brain. ArunA’s neural-derived exosomes, a form of EVs, are a new class of cell-free biologics and cell-mediated drug delivery systems to treat central nervous system and neurodegenerative disorders. This is the third study recently completed by ArunA, the first two of which demonstrated improved outcomes in middle-aged and aged mice following embolic stroke. Was neuroprotective Eliminated intracranial hemorrhage in ischemic lesions Improved behavior and mobility Decreased cerebral infarct volume and brain swelling Led to significant improvements at the tissue and functional levels###.
To view the results of this study, visit the publications page of the ArunA website. Since their discovery more than 30 years ago, extracellular vesicles-nanometer-sized cell-signaling particles- have been increasingly found to play a role in intercellular communication, capable of delivering functional proteins, mRNA transcripts and miRNA to cells throughout the body. Exosomes have the potential to target any cell in the body, exhibiting specificity for certain tissues. ArunA has established that its proprietary neural-derived exosomes cross the blood brain barrier and are internalized by neural tissue, delivering desired cargo to the CNS. The company’s stroke program has demonstrated the unique ability of its neural exosomes to enhance the nervous system’s protective mechanisms, leading to both structural and functional benefits in multiple preclinical models.
At ArunA Biomedical, we are the experts in the design, loading and scaling of neural-derived exosomes, developing a new class of cell-free biologics and cell-mediated drug delivery systems to treat CNS and neurodegenerative disorders.